135 related articles for article (PubMed ID: 38085855)
1. Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
Engström A; Wintzell V; Melbye M; Svanström H; Eliasson B; Gudbjörnsdottir S; Hveem K; Jonasson C; Hviid A; Ueda P; Pasternak B
Hepatology; 2024 Jun; 79(6):1401-1411. PubMed ID: 38085855
[TBL] [Abstract][Full Text] [Related]
2. Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study.
Pasternak B; Wintzell V; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Svanström H; Ueda P
Diabetes Care; 2020 Jun; 43(6):1326-1335. PubMed ID: 32295809
[TBL] [Abstract][Full Text] [Related]
3. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.
Ueda P; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Pasternak B
Diabetologia; 2021 Oct; 64(10):2204-2214. PubMed ID: 34254177
[TBL] [Abstract][Full Text] [Related]
4. Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study.
Ueda P; Wintzell V; Melbye M; Eliasson B; Söderling J; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Hviid A; Pasternak B
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1226-1237.e14. PubMed ID: 37716613
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.
Pasternak B; Wintzell V; Hviid A; Eliasson B; Gudbjörnsdottir S; Jonasson C; Hveem K; Svanström H; Melbye M; Ueda P
BMJ; 2024 Apr; 385():e078225. PubMed ID: 38683947
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.
Xu Y; Boyle TA; Lyu B; Ballew SH; Selvin E; Chang AR; Inker LA; Grams ME; Shin JI
J Gen Intern Med; 2024 May; 39(7):1112-1121. PubMed ID: 38191976
[TBL] [Abstract][Full Text] [Related]
7. Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.
van Dalem J; Driessen JHM; Burden AM; Stehouwer CDA; Klungel OH; de Vries F; Brouwers MCGJ
Hepatology; 2021 Nov; 74(5):2467-2477. PubMed ID: 34129693
[TBL] [Abstract][Full Text] [Related]
8. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
Ueda P; Wintzell V; Dahlqwist E; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Hviid A; Svanström H; Pasternak B
Diabetes Obes Metab; 2022 Mar; 24(3):473-485. PubMed ID: 34738703
[TBL] [Abstract][Full Text] [Related]
9. Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.
Svanström H; Ueda P; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Pasternak B
Lancet Diabetes Endocrinol; 2019 Feb; 7(2):106-114. PubMed ID: 30527909
[TBL] [Abstract][Full Text] [Related]
10. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
Simms-Williams N; Treves N; Yin H; Lu S; Yu O; Pradhan R; Renoux C; Suissa S; Azoulay L
BMJ; 2024 Apr; 385():e078242. PubMed ID: 38663919
[TBL] [Abstract][Full Text] [Related]
11. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
[TBL] [Abstract][Full Text] [Related]
12. Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes.
Elsaid MI; Li N; Firkins SA; Rustgi VK; Paskett ED; Acharya C; Reddy KR; Chiang CW; Mumtaz K
Aliment Pharmacol Ther; 2024 May; 59(9):1096-1110. PubMed ID: 38538967
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes.
Simon TG; Patorno E; Schneeweiss S
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1382-1393.e19. PubMed ID: 34256144
[TBL] [Abstract][Full Text] [Related]
14. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
[TBL] [Abstract][Full Text] [Related]
15. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
16. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.
Pasternak B; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Ueda P
BMJ; 2020 Apr; 369():m1186. PubMed ID: 32349963
[TBL] [Abstract][Full Text] [Related]
17. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Dawwas GK; Smith SM; Park H
Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
[TBL] [Abstract][Full Text] [Related]
18. Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.
Yang JY; Moon AM; Kim H; Pate V; Barritt AS; Crowley MJ; Buse JB; Stürmer T; Alexopoulos AS
J Diabetes Complications; 2020 Nov; 34(11):107706. PubMed ID: 32843283
[TBL] [Abstract][Full Text] [Related]
19. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
[TBL] [Abstract][Full Text] [Related]
20. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Bea S; Son H; Bae JH; Cho SW; Shin JY; Cho YM
Diabetes Obes Metab; 2024 Jan; 26(1):108-117. PubMed ID: 37735822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
